The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Oral Tablet
Capsule
Covance Clinical Research Unit, Inc
Daytona Beach, Florida, United States
Maximum Observed Plasma Concentration (Cmax) of AMG 510
Time frame: Day 1 and Day 9
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510
Time frame: Day 1 and Day 9
AUC from time Zero to Infinity (AUCinf) of AMG 510
Time frame: Day 1 and Day 9
Number of Participants with an Adverse Event (AE)
Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs.
Time frame: Day 1 to Day 11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.